Regeneron Q1 2024 10-Q Filed
Ticker: REGN · Form: 10-Q · Filed: 2024-05-02T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Regeneron's Q1 2024 10-Q is in, showing product and collaboration revenue details.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported financial results for the first quarter of 2024, detailing revenues and expenses. Specific product sales and collaboration revenues were highlighted, contributing to the overall financial performance.
Why It Matters
This filing provides investors with the latest financial performance data for Regeneron, crucial for understanding the company's current operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2024 Q1 — Reporting Period (First quarter of 2024)
- 2023-01-01 2023-03-31 — Prior Year Q1 (Comparison period for financial results)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer
- 20240331 (date) — Period of Report
- 20240502 (date) — Filing Date
- TARRYTOWN (location) — Business Address City
- NY (location) — Business Address State
FAQ
What were the total revenues for the first quarter of 2024?
The filing indicates financial results for the period ending March 31, 2024, but specific total revenue figures are not explicitly stated in the provided snippet.
What is Regeneron's primary business classification?
Regeneron Pharmaceuticals, Inc. is classified under Standard Industrial Classification code 2834, which is Pharmaceutical Preparations.
When was Regeneron Pharmaceuticals, Inc. incorporated?
The company was incorporated in New York (NY).
What is the company's mailing address?
The mailing address is 777 Old Saw Mill River Road, Tarrytown, NY 10591.
Are there any specific product revenue details mentioned for Q1 2024?
The filing references 'us-gaap:ProductMember' and 'regn:CollaborationRevenueMember' for the periods of 2024-01-01 to 2024-03-31, indicating product and collaboration revenues are tracked.
From the Filing
0001804220-24-000017.txt : 20240502 0001804220-24-000017.hdr.sgml : 20240502 20240502071311 ACCESSION NUMBER: 0001804220-24-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240502 DATE AS OF CHANGE: 20240502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 24905254 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 10-Q 1 regn-20240331.htm 10-Q regn-20240331 0000872589 12/31 2024 Q1 false 428 187 360 473 547 362 0000872589 2024-01-01 2024-03-31 0000872589 us-gaap:CommonClassAMember 2024-04-16 xbrli:shares 0000872589 us-gaap:CommonStockMember 2024-04-16 0000872589 2024-03-31 iso4217:USD 0000872589 2023-12-31 iso4217:USD xbrli:shares 0000872589 us-gaap:CommonClassAMember 2023-12-31 0000872589 us-gaap:CommonClassAMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:ProductMember 2024-01-01 2024-03-31 0000872589 us-gaap:ProductMember 2023-01-01 2023-03-31 0000872589 regn:CollaborationRevenueMember 2024-01-01 2024-03-31 0000872589 regn:CollaborationRevenueMember 2023-01-01 2023-03-31 0000872589 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0000872589 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-03-31 0000872589 2023-01-01 2023-03-31 0000872589 regn:CollaborationandContractManufacturingMember 2024-01-01 2024-03-31 0000872589 regn:CollaborationandContractManufacturingMember 2023-01-01 2023-03-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2023-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000872589 us-gaap:RetainedEarningsMember 2023-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2023-12-31 0000872589 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:CommonStockMember 2024-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000872589 us-gaap:RetainedEarningsMember 2024-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2024-03-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0000872589 us-gaap:CommonStockMember 2022-12-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000872589 us-gaap:RetainedEarningsMember 2022-12-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000872589 us-gaap:TreasuryStockCommonMember 2022-12-31 0000872589 2022-12-31 0000872589 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000872589 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000872589 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000872589 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000872589 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000872589 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0000872589 us-gaap:CommonStockMember 2023-03-31 000087258